These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27231256)

  • 21. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders.
    Christensen MC; Loft H; McIntyre RS
    J Affect Disord; 2018 Feb; 227():787-794. PubMed ID: 29689693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impacts of metabolic disruption, body mass index and inflammation on cognitive function in post-COVID-19 condition: a randomized controlled trial on vortioxetine.
    Kwan ATH; Le GH; Guo Z; Ceban F; Teopiz KM; Rhee TG; Ho R; Di Vincenzo JD; Badulescu S; Meshkat S; Cao B; Rosenblat JD; Dev DA; Phan L; Subramaniapillai M; McIntyre RS
    Ann Gen Psychiatry; 2024 Feb; 23(1):10. PubMed ID: 38424537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram.
    Levada OA; Troyan AS
    J Affect Disord; 2019 May; 250():114-122. PubMed ID: 30852363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The THINC-it Tool for Cognitive Assessment and Measurement in Major Depressive Disorder: Sensitivity to Change.
    McIntyre RS; Subramaniapillai M; Park C; Zuckerman H; Cao B; Lee Y; Iacobucci M; Nasri F; Fus D; Bowie CR; Tran T; Rosenblat JD; Mansur RB
    Front Psychiatry; 2020; 11():546. PubMed ID: 32670103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Minimal Clinically Important Difference of Executive Function Performance in Older Adults Who Fall: A Secondary Analysis of a Randomized Controlled Trial.
    Jehu DA; Davis JC; Madden K; Parmar N; Liu-Ambrose T
    Gerontology; 2022; 68(7):771-779. PubMed ID: 34657043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation of the University of California San Diego Performance-based Skills Assessment (UPSA) in major depressive disorder: Replication and extension of initial findings.
    Christensen MC; Sluth LB; McIntyre RS
    J Affect Disord; 2019 Feb; 245():508-516. PubMed ID: 30439678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of vortioxetine on functional capacity across different levels of functional impairment in patients with major depressive disorder: a University of California, San Diego Performance-based Skills Assessment (UPSA) analysis.
    Jacobson W; Zhong W; Nomikos GG; Christensen MC; Kurre Olsen C; Harvey PD
    Curr Med Res Opin; 2020 Jan; 36(1):117-124. PubMed ID: 31422713
    [No Abstract]   [Full Text] [Related]  

  • 28. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
    Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
    Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of Vortioxetine in Patients with Major Depressive Disorder in Real-World Clinical Practice: French Cohort Results from the Global RELIEVE Study.
    Polosan M; Rabbani M; Christensen MC; Simonsen K; Ren H
    Neuropsychiatr Dis Treat; 2022; 18():1963-1974. PubMed ID: 36068858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vortioxetine improves cognition in mild cognitive impairment.
    Tan SN; Tan C
    Int Clin Psychopharmacol; 2021 Nov; 36(6):279-287. PubMed ID: 34282748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study.
    Mattingly GW; Ren H; Christensen MC; Katzman MA; Polosan M; Simonsen K; Hammer-Helmich L
    Front Psychiatry; 2022; 13():824831. PubMed ID: 35356713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determination of a clinically important difference and definition of a responder threshold for the UCSD performance-based skills assessment (UPSA) in patients with major depressive disorder.
    Harvey PD; Jacobson W; Zhong W; Nomikos GG; Cronquist Christensen M; Kurre Olsen C; Merikle E
    J Affect Disord; 2017 Apr; 213():105-111. PubMed ID: 28213121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Augmenting Computerized Cognitive Training With Vortioxetine for Age-Related Cognitive Decline: A Randomized Controlled Trial.
    Lenze EJ; Stevens A; Waring JD; Pham VT; Haddad R; Shimony J; Miller JP; Bowie CR
    Am J Psychiatry; 2020 Jun; 177(6):548-555. PubMed ID: 32212856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
    Mahableshwarkar AR; Jacobsen PL; Chen Y
    Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder.
    Cao B; Park C; Subramaniapillai M; Lee Y; Iacobucci M; Mansur RB; Zuckerman H; Phan L; McIntyre RS
    Front Psychiatry; 2019; 10():17. PubMed ID: 30766492
    [No Abstract]   [Full Text] [Related]  

  • 37. A Feasibility Study of Patients with Major Depression and Substance Use Disorders: Vortioxetine as Maintenance Treatment.
    Basurte-Villamor I; Vega P; Roncero C; Martínez-Raga J; Grau-López L; Aguilar L; Torrens M; Szerman N
    Neuropsychiatr Dis Treat; 2022; 18():965-976. PubMed ID: 35547266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effectiveness of vortioxetine on neurobiochemical metabolites and cognitive of major depressive disorders patients: A 8-week follow-up study.
    Zhang Y; Lai S; Zhang J; Wang Y; Zhao H; He J; Huang D; Chen G; Qi Z; Chen P; Yan S; Huang X; Lu X; Zhong S; Jia Y
    J Affect Disord; 2024 Apr; 351():799-807. PubMed ID: 38311073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of antidepressant treatments on family functioning in adults with major depressive disorder: a post hoc comparison of vortioxetine and agomelatine.
    François C; Nielsen R; Danchenko N; Williams V; Lançon C
    Curr Med Res Opin; 2017 Jun; 33(6):1057-1066. PubMed ID: 28277865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study.
    Chokka P; Bougie J; Proulx J; Tvistholm AH; Ettrup A
    CNS Spectr; 2019 Dec; 24(6):616-627. PubMed ID: 30802419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.